To estimate the prevalence, characteristics and risk factors associated with the development of benzodiazepine dependence in the users of these active ingredients.
A representative sample of patients currently receiving benzodiazepine treatment for 1 month or longer (mean 38.2±52 months, range 1–360 months) was studied.
One thousand and forty eight (1048) consecutive patients attending 20 primary-care health centres of the Canary Islands Health Service participated in this study during 2002.
The severity of dependence scale (SDS) was used as a screening test of benzodiazepine dependence among patients using benzodiazepines.
Of patients using benzodiazepines for more than 1 month, 47% developed dependence to these compounds. Benzodiazepine dependence was more prevalent among women who were middle aged, separated, of low educational background, unemployed or housewives. Patients using short half-life benzodiazepines registered higher rates of dependence as well as those using higher doses or the patients with longer use. However, multivariate logistic regression analysis shows that benzodiazepine dependence was closely related only to three of the variables considered: the benzodiazepine dose used, the duration of this use and to the concomitant use of antidepressants.
The distribution of dose and length of treatment shows no evidence of pharmacological tolerance, neither in the whole sample nor in those patients with addiction (SDS+), reinforcing the idea that psychological dependence (addiction) is more relevant than pharmacological or physiological dependence in benzodiazepine chronic use.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
AAPM, APS, ASAM (2001) Consensus document from the American Academy of Pain Medicine, American Pain Society, and the American Society of Addiction Medicine. The American Academy of Pain Medicine, Glenview
American Psychiatric Association Task Force on Benzodiazepine Dependency (1990) Benzodiazepine dependence, toxicity, and abuse. American Psychiatric Association, Washington
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders IV (DSM-IV). Committee on Nomenclature and Statistics of the American Psychiatric Association, Washington
Bush P, Spector K, Rabin D (1984) Use of sedatives and hypnotics prescribed in a family practice. South Med J 77:677–681
Busto U, Sellers EM (1991) Pharmacological aspects of benzodiazepine tolerance and dependence. J Subst Abuse Treat 8:29–33
Ciraulo D, Sarid-Segal O (1991) Benzodiazepines: abuse liability. In: Roy-Byrne P, Cowley D (eds) Benzodiazepines in clinical practice: risks and benefits. American Psychiatric Press, Washington
De las Cuevas C, De la Fuente J, Sanz EJ, Cabrera C, Martín JM (1998) Factores asociados al consumo de benzodiacepinas. Psiquis 19:324–328
De las Cuevas C, Sanz EJ, De la Fuente JA, Cabrera C, Mateos A (1999) Prescribed daily doses and "risk factors" associated with the use of benzodiazepines in primary care. Pharmacoepidemiol Drug Saf 8:207–216
De las Cuevas C, Sanz E, De la Fuente J et al (2000) The severity of dependence scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction 95:245–250
Everitt BJ, Dickinson A, Robbins TW (2001) The neuropsychological basis of addictive behaviour. Brain Res Rev 36:129–138
Farnsworth M (1990) Benzodiazepine abuse and dependence: misconceptions and facts. J Fam Pract 31:393–400
Golombok S, Higgitt A, Fonagy P (1987) A follow-up study of patients treated for benzodiazepine dependence. Br J Med Psychol 60:141–149
Gossop M, Darke S, Griffiths P et al (1995) The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607–614
Greenblatt DJ, Shader RI (1974) Drug therapy, benzodiazepines. N Engl J Med 291:1239–1243
Hallstrom C, Lader M (1982) The incidence of benzodiazepine dependence in long-term users. J Psychiatr Treat Eval 4:293–296
Hawley CJ, Tattersale M, Dellaportas C, Hallstrom C (1994) Comparison of long-term benzodiazepine users in three settings. Br J Psychiatry 165:792–796
Helman C (1981) "Tonic", "fuel" and "food": social and symbolic aspects of the long-term use of psychotropic drugs. Soc Sci Med 15B:521–533
Helmuth L (2001) "Behavioral" addictions: do they exist? Science 294:980–984
Hyman SE, Arana GW (1987) Handbook of psychiatric drug therapy. Little, Brown, Boston, p 116
Kan CC, Breteler MH, Zitman FG (1997) High prevalence of benzodiazepine dependence in outpatients users, based on DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand 96:85–93
Kellet J (1974) The benzodiazepine bonanza. Lancet 2:964
Knoben JE, Anderson PO (1997) Handbook of clinical drug data, 8th edn. Appleton and Lange, London, pp 385–386
Nagy L, Krystal J, Woods S (1989) Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5-year naturalistic follow-up study. Arch Gen Psychiatry 46:993–999
Naja WJ, Pelissolo A, Hadad RS, Baddoura R, Baddoura C (2000) A general population survey on patterns of benzodiazepine use and dependence in Lebanon. Acta Psychiatr Scand 102:429–431
National Center on Addiction and Substance Abuse at Columbia University (CASA) (2000) Missed opportunity: national survey of primary care physicians and patients on substance abuse. CASA, New York
North D, McAvoy B, Powell A (1992) Benzodiazepine use in general practice—is it a problem? N Z Med J 105:287–289
Olfson M, Pincus HA (1994) Use of benzodiazepines in the community. Arch Intern Med 154:1235–1240
Pelissolo A, Bisserbe JL (1994) Dependence on benzodiazepines. Clinical and biological aspects. Encephale 20:147–157
Pollack MH, Tesai GE, Rosenbaum JF, Spier SA (1986) Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 6:302–304
Rickel K, Case G, Downing R, Winokur A (1983) Long-term diazepam therapy and clinical outcome. JAMA 250:767–771
Rickel F, Case G, Downing L, Fridman R (1986) One-year follow-up of anxious patients treated with diazepam. J Clin Psychopharmacol 6:32–36
Rickel K, Schweizer E, Weiss S, Zavadnick S (1993) Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. Arch Gen Psychiatry 50:61–68
Roth T, Roehrs T (1992) Issues in the use of benzodiazepine therapy. J Clin Psychiatry 53[Suppl 6]:14–18
Schweizer E, Rickel F, Weiss S, Zavodnick S (1993) Maintenance drug treatment of panic disorder. I. Results of a prospective placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 50:51–60
Shader R, Greenblatt D (1993) Use of benzodiazepines in anxiety disorder. N Engl J Med 328:1398–1405
Stein DJ, Stein MB, Goodwin W, Kumar R, Hunter B (2001) The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and less generalized social anxiety disorder. Psychopharmacology 158:267–272
Üstün B, Compton W, Mager D, Babor T et al (1997) WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results. Drug Alcohol Depend 47:161–169
Varia I, Rauscher F (2002) Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol 17:103–107
Warner JF (1994) 'Resolv'd to drink no more.' Addiction as a preindustrial concept. J Stud Alcohol 55:685–691
Wolff PO (1953) The activities of the WHO in drug addiction. Br J Addict 50:12–28
Woods J, Winger G (1995) Current benzodiazepine issues. Psychopharmacology 118:107–115
Woods J, Katz J, Winger G (1987) Abuse liability of benzodiazepines. Pharmacol Rev 39:241–413
World Health Organization (2000) Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistic Methodology, Oslo
Young LY, Koda-Kimble MA (1995) Applied therapeutics: the clinical use of drugs. Applied Therapeutics, Vancouver, pp 74–79
About this article
Cite this article
de las Cuevas, C., Sanz, E. & de la Fuente, J. Benzodiazepines: more "behavioural" addiction than dependence. Psychopharmacology 167, 297–303 (2003). https://doi.org/10.1007/s00213-002-1376-8